25 citations
,
July 1994 in “Journal of dermatological science”
Testosterone affects hair follicles differently across body sites, with beard hair follicles showing more activity of a specific enzyme and presence of androgen receptors compared to scalp hair.
Avicennia Marina extract and avicequinone C can reduce hair loss hormone production and increase hair growth factors, suggesting they could be used to treat androgenic alopecia.
Fluridil may decrease the number of androgen receptors in hair follicles by up to 95%. This suggests a different actionmechanism from other non-steroidal antiandrogens like RU58841, indicating they might be used together.
Hair loss treatments are generally categorized as anti-androgens, like finasteride and RU58841, which prevent hair loss by targeting DHT, and growth stimulators, such as minoxidil, rosemary oil, microneedling, and LLLT, which promote hair growth by increasing blood flow and growth factors. The user is seeking to confirm these categories and understand if there are other treatments or mechanisms of action.
The conversation discusses hair loss treatments beyond the commonly known three, focusing on separating effective treatments from myths. Dutasteride and low-dose oral Minoxidil are mentioned as having clinical evidence for increasing hair counts, but with potential side effects.
Hair loss treatments Finasteride, Dutasteride, Pyrilutamide, and RU58841 have different mechanisms of action. They can be used individually or stacked for better protection against hair loss.
PP405 and GT20029 are new hair loss treatments with different mechanisms from traditional options like Minoxidil and Finasteride. PP405 targets hair follicle stem cells to reactivate growth, while GT20029 works as an androgen receptor deleter, both requiring ongoing use for effectiveness.